Chronic Immune Thrombocytopenia Itp clinical trials

Explore recruiting chronic immune thrombocytopenia itp clinical trials.

Recruiting chronic immune thrombocytopenia itp studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Immune Thrombocytopenia Itp trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ARGX-113-2409: A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo- Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants from 12 Years to Less Than 18 Years of Age with Chronic ITP

Lithuania, Romania, Hungary, France, Italy, Spain +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients with Chronic Immune Thrombocytopenia (ITP)

Germany, Spain, Czechia, Italy, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP).

Hungary, Spain, Italy, Poland, Norway, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutaneous belimumab versus rituximab + placebo in adult patients with persistent or chronic immune thrombocytopenia (ITP)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Chronic Immune Thrombocytopenia Itp trials by city

Chronic Immune Thrombocytopenia Itp in Toronto Chronic Immune Thrombocytopenia Itp in Vancouver Chronic Immune Thrombocytopenia Itp in Montreal Chronic Immune Thrombocytopenia Itp in Calgary Chronic Immune Thrombocytopenia Itp in Edmonton Chronic Immune Thrombocytopenia Itp in Ottawa Chronic Immune Thrombocytopenia Itp in Winnipeg Chronic Immune Thrombocytopenia Itp in Quebec City Chronic Immune Thrombocytopenia Itp in Hamilton Chronic Immune Thrombocytopenia Itp in Kitchener Chronic Immune Thrombocytopenia Itp in London Chronic Immune Thrombocytopenia Itp in Halifax Chronic Immune Thrombocytopenia Itp in New York Chronic Immune Thrombocytopenia Itp in Los Angeles Chronic Immune Thrombocytopenia Itp in Chicago Chronic Immune Thrombocytopenia Itp in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease